Valium 10 mg

Clinical Monograph: Valium 10 mg (Diazepam)

1. Classification and Chemical Overview

Diazepam is a long-acting 1,4-benzodiazepine derivative. Chemically designated as 7-chloro-1,3-dihydro-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one. Under the Anatomical Therapeutic Chemical (ATC) system, diazepam is indexed under N05BA01.

• Product Context: Valium 10 mg represents a high therapeutic unit strength typically utilized for severe clinical presentations, muscle spasm management, or established maintenance protocols.

• Controlled Status: Classified as a Controlled Substance (Schedule IV under the US CSA; Schedule 4 / Prescription Only Medicine internationally) due to its high potential for physical dependence, misuse liability, and central nervous system depression risks.

2. Mechanism of Action and Pharmacodynamics

Diazepam acts as a positive allosteric modulator at central nervous system FRENTEA​ receptor complexes:

• Receptor Binding: Binds selectively to benzodiazepine binding sites on FRENTEA​ receptors throughout the limbic system, thalamus, and spinal cord.

• Chloride Conductance Enhancement: Facilitates GABA-mediated opening of chloride ion channels, hyperpolarizing neuronal membranes and reducing neuronal excitability.

• Muscle Relaxant Properties: Exerts central skeletal muscle relaxation by inhibiting polysynaptic reflex pathways at the spinal cord level.

3. Approved Clinical Indications and Dosing Scope

Licensing for diazepam includes:

• Anxiety Disorders: Management of severe anxiety states or short-term relief of anxiety symptoms.

• Acute Alcohol Withdrawal: Symptomatic management of acute alcohol withdrawal syndrome (delirium tremens).

• Skeletal Muscle Spasm: Adjunctive treatment for relief of reflex muscle spasm due to local pathology, trauma, or spasticity.

• Seizure Disorders: Adjunctive management of convulsive disorders (though rarely used as chronic monotherapy for epilepsy).

Dosing & Administration Regimen:

• Individualized Titration: Initial doses for anxiety typically range from 2 mg to 10 mg, whereas the 10 mg strength is reserved for more severe clinical states, acute alcohol withdrawal, or established maintenance protocols.

• Duration Restrictions: Use for anxiety should be short-term (typically 2 to 4 weeks) with gradual taper protocols to prevent severe withdrawal reactions upon discontinuation.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and completely absorbed following oral administration, with peak plasma concentrations (Cmax​) attained within 30 minutes to 2 hours.

• Distribution: Highly lipophilic; distributes widely into body tissues and readily crosses the blood-brain barrier and placenta. Plasma protein binding is very high (~98% to 99%).

• Biotransformation: Extensively metabolized in the liver via Cytochrome P450 enzymes (CYP2C19 y CYP3A4) into active metabolites with long elimination half-lives:

  • Converted into desmethyldiazepam (nordazepam), oxazepam, y temazepam, all of which possess sedative and anxiolytic activity.

• Elimination: Excreted primarily via the kidneys in urine as conjugated metabolites. The terminal elimination half-life of diazepam is prolonged (20 to 50 hours), and its active metabolite nordazepam exhibits a half-life ranging from 30 to 100 hours, contributing to significant drug accumulation upon repeated dosing.

5. Physiological Effects and Adverse Event Spectrum

Valium suppresses central nervous system arousal, motor coordination, respiratory drive, and cognitive processing.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Somnolence, fatigue, sedation, ataxia, dizziness, impaired coordination.

• Common ($\ge 1/100$ to $<1/10$): Confusion, depression, dysarthria, headache, tremor, constipation, nausea, dry mouth, hypotension.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Paradoxical reactions (aggressiveness, rage, excitation, hallucinations), urinary retention, changes in libido, skin rashes, visual disturbances.

• Rare / Severe (<1/1,000): Respiratory depression, apnea, jaundice, blood dyscrasias, severe withdrawal seizures, anaphylaxis.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindicaciones

• Known hypersensitivity to diazepam or other benzodiazepines.

• Severe acute respiratory insufficiency or sleep apnea syndrome.

• Myasthenia gravis.

• Severe hepatic impairment.

• Acute narrow-angle glaucoma.

Key Drug Interactions

• Opioids & CNS Depressants: Co-administration with opioids, alcohol, barbiturates, or sedatives causes synergistic central nervous system and respiratory depression, dramatically increasing the risk of coma and fatal overdose.

• CYP2C19 & CYP3A4 Inhibitors (e.g., Cimetidine, Ketoconazole, Omeprazole): Inhibit diazepam metabolism, prolonging clearance and escalating plasma levels and sedation risks.

• CYP Inducers (e.g., Rifampicin, Carbamazepine): Accelerate diazepam clearance, reducing therapeutic efficacy.

Clinical Precautions and Monitoring

• Boxed Warning (Concomitant Opioid Use & Abuse/Dependence): Combined use of benzodiazepines and opioids increases the risk of profound sedation, respiratory depression, coma, and death. Diazepam carries a high risk of physical dependence and psychological addiction; abrupt cessation can precipitate a severe, life-threatening withdrawal syndrome characterized by tremors, psychosis, and grand mal seizures.

• Accumulation Risk in Elderly: Due to its long half-life and active metabolites, diazepam accumulates extensively in elderly or frail patients, leading to excessive sedation, cognitive impairment, ataxia, and heightened risk of falls and hip fractures; lower initial doses or alternative short-acting agents are strongly preferred.